Live Breaking News & Updates on Heather landau

Stay informed with the latest breaking news from Heather landau on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Heather landau and stay connected to the pulse of your community

Immix Biopharma 12 Month Review Progress Update

Immix Biopharma 12 Month Review Progress Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United-states , Stanford , California , Boston-university , Massachusetts , Boston , San-diego , American , Heather-landau , Henrya-mckinnell , Gabriel-morris , Ilya-rachman

Looking Ahead: Future Perspectives on AL Amyloidosis

Heather Landau, MD, invites panelists to provide their insights on the future outlook for the treatment of AL amyloidosis.

Vaishali-sanchorawala , Jeffrey-zonder , Heather-landau , Peer-exchange , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab , Vital , Pronto , Affirm-al , Nexicart-1

NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis

Faculty offer insights on the NEXICART-1 phase 1 clinical trial investigating the safety and efficacy of NXC-201 in patients with AL amyloidosis and discuss potential clinical implications on the study’s findings.

United-states , American , Vaishali-sanchorawala , Heather-landau , Jeffrey-zonder , Peer-exchange , American-society-of-hematology , American-society , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab

Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials

Vaishali Sanchorawala, MD, provides insights on the pooled safety analysis of data from phase 1 to 3 trials, including PRONTO and VITAL, which investigated the use of birtamimab in patients with light chain (AL) amyloidosis.

United-states , American , Vaishali-sanchorawala , Heather-landau , Jeffrey-zonder , Peer-exchange , American-society-of-hematology , American-society , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab

The Potential Role of CAR T Therapy in AL Amyloidosis

A panel of expert oncologists discuss the underlying rationale and potential role for CAR T therapy in patients with AL amyloidosis.

Heather-landau , Jeffrey-zonder , Vaishali-sanchorawala , Peer-exchange , Light-chain-amyloidosis , Al-amyloidosis , Andromeda , Daratumumab , Vital , Pronto , Affirm-al , Nexicart-1

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

University-of-alabama-at-birmingham , Alabama , United-states , New-york , Grand-view , Ohio , Cincinnati , Memorial-sloan-kettering-cancer-center , Colorado , American , Mike-moyer , Heather-landau

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

United-states , American , Vaishali-sanchorawala , Heather-landau , Susan-bal , Immix-biopharma-inc , Amyloidosis-program , Boston-university-school-of-medicine , Memorial-sloan-kettering-cancer-center , American-society-for-hematology , University-of-alabama-at-birmingham , Nasdaq

Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board

Dr. Landau joins the Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Memorial Sloan Kettering Cancer Center Dr. Landau is a recognized thought...

Memorial-sloan-kettering-cancer-center , New-york , United-states , Colorado , California , Los-angeles , Heather-landau , Mike-moyer , Gabriel-morris , Ilya-rachman , Amyloidosis-program , Exchange-commission

Nexcella Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board

Nexcella Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Colorado , United-states , New-york , California , Memorial-sloan-kettering-cancer-center , Gabriel-morris , Ilya-rachman , Los-angeles , Mike-moyer , Heather-landau , Amyloidosis-program , University-of-colorado

Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board

Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

California , United-states , New-york , Colorado , Memorial-sloan-kettering-cancer-center , Mike-moyer , Ilya-rachman , Gabriel-morris , Los-angeles , Heather-landau , Amyloidosis-program , University-of-colorado